menu
    • menu

    Company profile for Zhejiang Hengkang Pharmaceutical

    Zhejiang Hengkang-PSE
    News
    Hengkang Pharma invites global customers to join CPHI exhibition

    08 Oct 2024

    // PRESS RELEASE

    CPHI Milan 2024 Zhejiang Hengkang Pharm

    24 Sep 2024

    // PRESS RELEASE

    Kactus Biosystems and Hengkang Pharma reached a strategic cooperation

    22 May 2023

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Zhejiang Hengkang Pharmaceutical

    Contact Supplier

    Website

    Pharmex Middle East

    Booth #76/1

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/cep-q1-2026-update-cep-2-0-edqm-s-new-guidelines-strengthen-ecosystem-indian-firms-top-list-of-ceps-issued

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.

    Related CompaniesRelated Companies

    About

    Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming to global API standards, along with professional R&D and marketing teams, Hengkang’s operations span major pharmaceutical markets such as China, Europe, the CIS region, Japan, and South Korea. Hengkang has established long-term and stable relationships with nearly 70 countries overseas and hundreds of domestic enterprises. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Zhejiang Hengkang PharmaceuticalChina Flag
    Country
    Country
    China
    Address
    Address
    11 Chengen Road, Pubagang Town, Sanmen County, Zhejiang Province, Zip code: 31...
    Telephone
    Telephone
    +86 57683372028
    Client Email
    Email
    marketing@hengkangpharm.cn
    Client Website
    Website
    https://en.hengkangpharm.cn/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/zhejiang-hengkang-pharmaceutical-co-ltd/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Pharmex Middle East

    Booth #76/1

    envelop Contact Supplier

    Pharmex Middle East

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/zhejiang-hengkang-pharmaceutical-party-content-9876.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/zhejiang-hengkang-pharmaceutical-party-content-76993.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/zhejiang-hengkang-pharmaceutical-party-content-11530.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15978

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Hengkang Pharma invites global customers to join CPHI exhibition
    Hengkang Pharma invites global customers to join CPHI exhibition

    08 Oct 2024

    // PRESS RELEASE

    https://en.hengkangpharm.cn/index.php/news/cphi-milan-2024-zhejiang-hengkang-pharm/

    PRESS RELEASE
    08 Oct 2024
    Share Share
    CPHI Milan 2024 Zhejiang Hengkang Pharm
    CPHI Milan 2024 Zhejiang Hengkang Pharm

    24 Sep 2024

    // PRESS RELEASE

    https://en.hengkangpharm.cn/index.php/news/cphi-milan-2024-zhejiang-hengkang-pharm/

    PRESS RELEASE
    24 Sep 2024
    Share Share
    Kactus Biosystems and Hengkang Pharma reached a strategic cooperation
    Kactus Biosystems and Hengkang Pharma reached a strategic cooperation

    22 May 2023

    // PRESS RELEASE

    http://hengkangpharm.cn/new_detail_en/id/8.html

    PRESS RELEASE
    22 May 2023
    Share Share
    KaiKa Biotechnology and HengKang Reach Strategic Cooperation
    KaiKa Biotechnology and HengKang Reach Strategic Cooperation

    28 Feb 2023

    // PRESS RELEASE

    http://hengkangpharm.cn/new_detail/id/18.html

    PRESS RELEASE
    28 Feb 2023
    Share Share
    Zhejiang Hengkang Meiji Pharma to enter the field of green synthetic biology
    Zhejiang Hengkang Meiji Pharma to enter the field of green synthetic biology

    10 Jan 2023

    // PRESS RELEASE

    http://hengkangpharm.cn/new_detail_en/id/6.html

    PRESS RELEASE
    10 Jan 2023
    Share Share
    Vienna Tides EURO 2022 meet for Phosphoramidite for oligonucleotides
    Vienna Tides EURO 2022 meet for Phosphoramidite for oligonucleotides

    18 Nov 2022

    // PRESS RELEASE

    http://hengkangpharm.cn/new_detail_en/id/3.html

    PRESS RELEASE
    18 Nov 2022
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company
    Hengkang

    ABOUT THIS PAGE

    Contact Zhejiang Hengkang Pharmaceutical and get a quotation

    Zhejiang Hengkang Pharmaceutical is a supplier offers 60 products (APIs, Excipients or Intermediates).

    Find Mesalazine bulk with DMF, CEP, JDMF offered by Zhejiang Hengkang Pharmaceutical

    Find Deferasirox bulk with DMF, CEP offered by Zhejiang Hengkang Pharmaceutical

    Find Mesalazine bulk with CEP, JDMF offered by Zhejiang Hengkang Pharmaceutical

    Find Acemetacin bulk with CEP offered by Zhejiang Hengkang Pharmaceutical

    Find Amiodarone Hydrochloride bulk with CEP offered by Zhejiang Hengkang Pharmaceutical

    Find Benserazide Hydrochloride bulk with CEP offered by Zhejiang Hengkang Pharmaceutical

    Find Eltrombopag bulk with DMF offered by Zhejiang Hengkang Pharmaceutical

    Find Pranlukast Hydrate bulk with JDMF offered by Zhejiang Hengkang Pharmaceutical

    Find Tenoxicam bulk with CEP offered by Zhejiang Hengkang Pharmaceutical

    Find Vancomycin Hydrochloride bulk with WC offered by Zhejiang Hengkang Pharmaceutical

    Find Vonoprazan Fumarate bulk with DMF offered by Zhejiang Hengkang Pharmaceutical

    Find DMT-2'-O-ME-G(IBU)-CE PHOSPHORAMIDITE bulk with DMF offered by Zhejiang Hengkang Pharmaceutical

    Find Tenoxicam, Pubagang site bulk with CEP offered by Zhejiang Hengkang Pharmaceutical

    Find Amiodarone Hydrochloride bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Carbocysteine Lysine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Favipiravir bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Midecamycin bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Acalabrutinib bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Acoramidis Hydrochloride bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Ademetionine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Ademetionine 1,4-Butanedisulfonate bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Ademetionine Disulfate Tosylate bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Apixaban bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Aprocitentan bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Bilastine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Carbocisteine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Ciprofibrate bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Clascoterone bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Daridorexant Hydrochloride bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Delgocitinib bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Doravirine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Dotinurad bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Elsulfavirine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Esmolol Hydrochloride bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Etravirine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Fenofibrate bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Iguratimod bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Ilaprazole bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Lemborexant bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Lorundrostat bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Lysine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Mirabegron bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Mirdametinib bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Otilonium Bromide bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Perampanel bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Pyrroloquinoline Quinone bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Resmetirom bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Rimegepant Sulfate bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Riociguat bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Rotigotine bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Roxadustat bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Safinamide Methanesulfonate bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Salcaprozate Sodium bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Saxagliptin bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Sparsentan bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Tauroursodeoxycholic Acid bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Tenapanor Hydrochloride bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Upadacitinib bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Vericiguat bulk offered by Zhejiang Hengkang Pharmaceutical

    Find Viloxazine Hydrochloride bulk offered by Zhejiang Hengkang Pharmaceutical

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search